>>157 ¿ʬ¤³¤ì¤À¤È»×¤¤¤Þ¤¹¡£¤½¤Î¤È¤ª¤ê¤ÎÎÅË¡¤«¤ÏÉÔÌÀ¤Ç¤¹¤¬¡£ http://www.sbccsg.org/study.html ±ê¾ÉÀÆý´â¤ËÂФ¹¤ë²½³Ø¡¦Êü¼ÍÀþÎÅË¡¤Î¸¡Æ¤¡ÊSBCCSG-04) AP followed by weekly paclitaxel¤Ë¤è¤ë½ÑÁ°²½³ØÎÅË¡¤Î ¸¡Æ¤¡ÊSBCCSG-07)
A phase II study of doxorubicin plus paclitaxel followed by weekly paclitaxel as neoadjuvant chemotherapy for breast cancer (SBCCSG-07). K. Inoue, H. Takei, M. Kurozumi, K. Futsuhara, T. Kai, T. Kuroda, S. Ueda, H. Miyake, Y. Hakamada, K. Suemasu, T. TabeiJournal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 11103